Milestones etc.

Important Scientific milestones in 2017:
One publication (ref. 1) supporting that WHO performance status (0-1 favorable) and comorbidity (ASA 1 favorable) were factors of importance for survival, whereas measures of health-related quality of life (HRQL) were not.   

Most important funding sources in 2017:
Local money from UiO
Some funding from medical companies regarding oncological studies

Most important application activity (for external funding) in 2017:
Part of application to Kreftforeningen and Helse Sør Øst

Short bullet point self-assessment of the group’s strengths and improvement areas/points
Strengths:

  • The largest unit in Norway doing non-surgical and surgical treatment for esophageal- and gastric cancer
    Improvements:
  • To recruit a research fellow
  • To apply for funding
  • Further develop ongoing cooperation with Department of Molecular Oncology, OUS

Popular scientific contributions (newspaper/magazine chronicles, blog-posts, open lectures etc.):
Responsible for National Meeting for Surgeons (April 20. 2017) organized by NFGK and NGICG with presentations on epidemiology, work-up and treatment of esophageal and gastric cancer

3 most important publications from the two last years (2017 and 2016):
Year 2017:

  • Amdal CD, Jacobsen AB, Falk RS, Johnson E, Os SS, Warloe T, Bjordal K. Improved treatment decisions in patients with esophageal cancer. Acta Oncol.2017 Oct;56(10):1286-1294.
  • Galleberg RB, Knigge U, Tiensu JE, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Grønbæk H, Österlund P, Hjortland GO, Assmus J, Tang L, Perren A. Sorbye H. Results after surgical treatment in patients with high-grade gastroenteropancreativ neuroendocrine carcinomas. Eur J Surg Oncol 2017; 43 (9):1682-89.

Year 2016:

  • Grøtting MS, Løberg EM, Johannessen H-O, Johnson E. Reseksjon for oesophaguscancer –
    komplikasjoner og overlevelse. Tidsskr Nor Legeforen 2016; 136(9):809-14.
 
Scroll to top